Interpace Biosciences Inc. (IDXG): Guggenheim on fence with Amgen in premar...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Re: None

Friday, 04/17/2020 1:43:39 PM

Friday, April 17, 2020 1:43:39 PM

Guggenheim on fence with Amgen in premarket analyst action https://seekingalpha.com/news/3560770-guggenheim-on-fence-amgen-in-premarket-analyst-action

Keep Last Read

Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:29:42 PM
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:01:48 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:33:32 AM
Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:05:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:05:29 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 10:14:32 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:16:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:05:18 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/22/2023 08:53:38 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/22/2023 08:20:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 07:47:52 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 05:27:44 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2023 09:24:47 PM

InvestorsHub NewsWire

Only $200 per official company press release!